Linked Life Data

3813579

Source:http://linkedlifedata.com/resource/pubmed/id/3813579

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
1987-3-11
pubmed:abstractText
Twenty-five patients with primary or metastatic brain tumor were treated with two administrations of MCNU, 67-125 mg/m2 i.v., at 1-293 day intervals. Thrombocytopenia of less than 10 X 10(4)/mm8 occurred in 9 cases (36.0%) and leukocytopenia of less than 3 X 10(3)/mm3 in 11 cases (44.0%). The factors influencing these two kinds of bone marrow suppression were investigated using discriminant analysis (SPSS software package). The most influential factor for thrombocytopenia was the dose of MCNU and that for leukocytopenia was the interval between the two administrations. These results show that patients should be able to receive this drug without suffering bone marrow suppression if care is taken with regard to their condition with the time interval between doses.
pubmed:language
jpn
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Feb
pubmed:issn
0385-0684
pubmed:author
pubmed:issnType
Print
pubmed:volume
14
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
511-5
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed:year
1987
pubmed:articleTitle
[Discriminant analysis of bone marrow suppression of methyl 6-[3-(2-chloroethyl)-3-nitrosoureido]-6-deoxy-alpha-D-glucopyranoside (MCNU)].
pubmed:publicationType
Journal Article, English Abstract